Dr. Noble is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8700 Beverly Blvd
Ste 2119
West Hollywood, CA 90048Phone+1 310-423-1888Fax+1 310-423-2665
Education & Training
- University of ColoradoFellowship, Pulmonary Disease and Critical Care Medicine, 1988 - 1991
- University of California (San Francisco)Chief Residency, Internal Medicine, 1987 - 1988
- University of California (San Francisco)Residency, Internal Medicine, 1984 - 1987
- New York University School of MedicineClass of 1984
Certifications & Licensure
- CA State Medical License 2012 - 2026
- NC State Medical License 2006 - 2014
- CT State Medical License 1998 - 2007
- MD State Medical License 1992 - 1999
- CO State Medical License 1989 - 1993
- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 2 citationsPanel stacking is a threat to consensus statement validity.Kasper P Kepp, Preben Aavitsland, Marcel Ballin, Francois Balloux, Stefan Baral
Journal of Clinical Epidemiology. 2024-09-01 - Aging-Associated Molecular Changes in Human Alveolar Type I Cells.Xue Liu, Xuexi Zhang, Jiurong Liang, Paul W Noble, Dianhua Jiang
Journal of Respiratory Biology and Translational Medicine. 2024-09-01 - 3 citationsPhase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis.Waldo L L D Mattos, Nasreen Khalil, Lisa G Spencer, Francesco Bonella, Rodney J Folz
American Journal of Respiratory and Critical Care Medicine. 2024-08-15
Press Mentions
- Pulmonary Fibrosis Foundation Adds Cedars-Sinai to Care Center NetworkDecember 23rd, 2022
- Cedars-Sinai Named to Pulmonary Fibrosis Foundation Care Center NetworkDecember 16th, 2022
- Lassen Therapeutics Announces the Appointment of a Highly Experienced Biotech Executive to Its Board of Directors and the Expansion of Its Scientific and Clinical Advisory Board with Leading Experts in Pulmonary Fibrosis and Clinical DevelopmentOctober 7th, 2021
- Join now to see all
Grant Support
- Innate Immune Mechanisms In Non-Infectious Lung InflammationNational Institute Of Allergy And Infectious Diseases2008–2012
- Matrix Regulation Of Pulmonary FibrosisNational Heart, Lung, And Blood Institute2011
- Regulation Of Pulmonary Fibrosis By CXCR3National Heart, Lung, And Blood Institute2006–2011
- Interdisciplinary Training Program In Lung DiseaseNational Heart, Lung, And Blood Institute2006–2011
- Mechanisms Of Macrophage Activation In Lung InflammationNational Heart, Lung, And Blood Institute2006–2010
- Matrix Regulation Of Fibroproliferative Lung DiseaseNational Heart, Lung, And Blood Institute2006–2010
- Immune Mechanisms In Non-Infectious Lung InflammationNational Institute Of Allergy And Infectious Diseases2006
- Survivin Regulation Of Pulmonary FibrosisNational Heart, Lung, And Blood Institute2006
- Regulation Of Pulmonary Fibrosis By CXCR3National Heart, Lung, And Blood Institute2005–2006
- Survivin Regulation Of Pulmonary FibrosisNational Heart, Lung, And Blood Institute2003–2005
- Immune Mechanisms In Non-Infectious Lung InflammationNational Institute Of Allergy And Infectious Diseases2002–2005
- Mechanisms Of Macrophage Activation In Lung InflammationNational Heart, Lung, And Blood Institute1997–2005
- Regulation Of Macrophage Phenotypes In Lung RepairNational Heart, Lung, And Blood Institute1992–1996
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: